Encysive Pharmaceuticals INC
SEC CIK 887023 · ENCY · last insider filing 2008-06-10
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Cruikshank Robert J | Director | filed 2006 - 2008 |
| Dixon Richard A F | Director · Sr. V.P. Research & CSO | filed 2006 - 2008 |
| Thomson James A | Director | filed 2006 - 2008 |
| Foran Margaret M | Director | filed 2008 - 2008 |
| Mackay Martin | Director | filed 2008 - 2008 |
| Giordano Douglas E. | Director | filed 2008 - 2008 |
| Reid David | Director | filed 2008 - 2008 |
| Pietruski John M | Director | filed 2006 - 2008 |
| Buchi J Kevin | Director | filed 2006 - 2008 |
| Willerson James T | Director | filed 2006 - 2008 |
| Oparil Suzanne | Director | filed 2006 - 2008 |
| Anderson Ronald J | Director | filed 2006 - 2008 |
| Dillon John H II | Director | filed 2006 - 2008 |
| Cole George W | Director · President and CEO | filed 2006 - 2008 |
| Given Bruce D | Director · President & CEO | filed 2006 - 2007 |
| Carlucci Frank C | Director | filed 2006 - 2006 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Maetzold Derek J | V.P., Marketing & Sales | filed 2006 - 2008 |
| Manierre Paul S | V.P. and General Counsel | filed 2006 - 2008 |
| Keyser D Jeffrey | V.P., Regulatory Affairs | filed 2007 - 2008 |
| Goeggel Richard A | V.P., Finance & Corp Treasurer | filed 2007 - 2008 |
| Busenbark Gordon H | Chief Financial Officer | filed 2006 - 2007 |
| Mueller Stephen L | V.P. Finance & Administration | filed 2006 - 2006 |
| Coyne Terrance C | V.P., Clinical Develop. & CMO | filed 2006 - 2006 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.